PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24331979-6 2014 Moreover, the treatments of PF573228, Y27632 and cytochalasin D promoted p38 and ERK1/2 phosphorylations, and the treatments of U0126 and SB203580 decreased p38 and ERK1/2 phosphorylations, respectively. Cytochalasin D 49-63 mitogen-activated protein kinase 1 Homo sapiens 73-76 29605806-8 2018 Moreover, treating hMSCs by Cytochalasin D inhibited ERK and Smad2 signaling and this was associated with enhanced adipocyte differentiation. Cytochalasin D 28-42 mitogen-activated protein kinase 1 Homo sapiens 53-56 20814573-8 2010 Disrupting stress fiber contractile function with cytochalasin D or Y27632 decreased the levels of JNK and ERK phosphorylation. Cytochalasin D 50-64 mitogen-activated protein kinase 1 Homo sapiens 107-110 11969294-4 2002 Use of PD98059 to inhibit MAPK/Erk and cytochalasin D (Cyto D) to disrupt the actin CSK at progressive time points in G(1) revealed that the requirement for MAPK/Erk activation lasts only to mid-G(1), while the actin CSK must remain intact up to late G(1) restriction point, R, in order for capillary endothelial cells to enter S phase. Cytochalasin D 39-53 mitogen-activated protein kinase 1 Homo sapiens 162-165 16461767-10 2006 Further, cytochalasin D inhibited FAK phosphorylation and cleavage, cell adhesion, locomotion, and ERK phosphorylation, thus showing FAK activation downstream of actin assembly. Cytochalasin D 9-23 mitogen-activated protein kinase 1 Homo sapiens 99-102 17825818-7 2007 Finally, C3G- and C3GDeltaCat-mediated inhibition of ERK phosphorylation is reverted by incubation with cytochalasin D. Cytochalasin D 104-118 mitogen-activated protein kinase 1 Homo sapiens 53-56 15855657-6 2005 Activation of ERK was attenuated by drugs that disassemble the actin cytoskeleton (cytochalasin D, latrunculin B), and these compounds interfered with the activation of ERK by mitogen-activated protein kinase kinase (MEK). Cytochalasin D 83-97 mitogen-activated protein kinase 1 Homo sapiens 14-17 15855657-6 2005 Activation of ERK was attenuated by drugs that disassemble the actin cytoskeleton (cytochalasin D, latrunculin B), and these compounds interfered with the activation of ERK by mitogen-activated protein kinase kinase (MEK). Cytochalasin D 83-97 mitogen-activated protein kinase 1 Homo sapiens 169-172 12907684-4 2003 CD treatment did not affect ERK-1/-2 activation but blocked the signaling events necessary for NO-induced dedifferentiation, apoptosis, and COX-2 expression such as activation of p38 kinase and inhibition of PKCalpha and -zeta. Cytochalasin D 0-2 mitogen-activated protein kinase 1 Homo sapiens 179-182 12907684-5 2003 CD also suppressed activation of downstream signaling of p38 kinase and PKC, such as NF-kappaB activation, p53 accumulation, and caspase-3 activation, which are necessary for NO-induced apoptosis. Cytochalasin D 0-2 mitogen-activated protein kinase 1 Homo sapiens 57-60 12907684-7 2003 The down-regulation of PI 3-kinase and Akt was blocked by CD treatment, and the CD effects on apoptosis, p38 kinase, and PKCalpha and -zeta were abolished by the inhibition of PI 3-kinase with LY294002. Cytochalasin D 80-82 mitogen-activated protein kinase 1 Homo sapiens 105-108 10984494-11 2000 Strain increased ERK-dependent AP-1 nuclear protein binding, which was attenuated by cytochalasin D and 8-Br-cGMP. Cytochalasin D 85-99 mitogen-activated protein kinase 1 Homo sapiens 17-20 9566877-4 1998 Cytochalasin D treatment of fibroblasts inhibited FN-induced FAK in vitro kinase activity and signaling to ERK2, but it only partially inhibited c-Src activation. Cytochalasin D 0-14 mitogen-activated protein kinase 1 Homo sapiens 107-111